

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Omalizumab for previously treated chronic spontaneous urticaria**

**Batch 34**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable – no potential equality issues were identified for consideration by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes was made to the draft scope because no potential equality issues were identified.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No potential equality issues were identified, which meant that there were no additional stakeholders relating to equality issues who needed to be added to the matrix.

**Approved by Associate Director (name):** Elisabeth George

**Date:** 12/05/2014